Form 4/A for AVIR Atea Pharmaceuticals, Inc.
Accepted 2026-05-21 18:30:02 ET · period of report 2026-05-18 · accession 0001193125-26-235039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2026-05-21 18:30 | 2026-05-18 | AVIR | Murphy Polly A. | Dir | P - Purchase | $4.17 | +6,100 | 92.1K | +7% | +$25.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | P | A | 6,100 | $4.17 | 92,145 | D | — | — | (F1) This Form 4/A has been filed solely to correct the date of the transaction reported in Column 2 of Table I of the Reporting Person's Form 4 filed on May 20, 2026, which was inadvertently noted as "May 18, 2025" instead of "May 18, 2026." (F2) The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |